期刊文献+

纳米粒穿透血脑屏障机制的研究进展 被引量:2

Progress in mechanisms of nanoparticles across the blood-brain barrier
下载PDF
导出
摘要 血脑屏障(blood-brain barrier,BBB)的存在使98%的药物无法进入脑组织,是制约神经系统药物发展的重要因素。纳米粒载药系统能够透过BBB,并提高脑内药物浓度,是实现脑内靶向给药的良好载体,但其透过BBB的机制至今尚未完全明白。自从2001年Kreuter提出关于纳米粒(nanoparticles,NP)透过BBB的6点可能机制后,针对此机制并进而提高载药NP入脑效率的探讨已成为热点之一,文中就目前NP穿透BBB机制研究进展做一综述。 The existence of blood-brain barrier(BBB) makes it impossible for 98% medicines to enter the brain.This is an important restrictive factor for the development of central nervous drugs.By nanoparticle delivery system,drugs can cross the BBB and increase the drug concentration in brain.This system is a better carrier for drugs to target brain,but the mechanism how it permeate the BBB is not completely understood.Since Kreuter proposed six plausible mechanisms for nanoparticles(NP) across the BBB in 2001,it has become a hot spot to investigate these mechanisms in order to enhance the drug-loaded NP permeability across the BBB.This article mainly reviewed the present research progress in mechanisms of NP across the BBB.
出处 《中国新药杂志》 CAS CSCD 北大核心 2008年第21期1831-1833,共3页 Chinese Journal of New Drugs
基金 福建省自然科学基金(2006J0188)
关键词 纳米粒 血脑屏障 靶向药物 药物载体 中枢神经系统 nanoparticles blood-brain barrier drug targeting drug carriers central nervous system
  • 相关文献

参考文献20

  • 1DE BOER AG, GAILLARD PJ. Drug targeting to the brain[J]. Annu Rer Pharmacol Toxicol, 2007, 47( 1 ) :323 -355.
  • 2GILMORE JL,YI X. QUAN L. et al. Novel nanomaterials for clinical neuroscience[ J ]. J Neuroimmune Pharmacol, 2008, 3(2) :85 -94.
  • 3KREUTER J.Nanoparticulate svstems for brain delivery of drugs[J]. Adr Drug Delir Rer. 2001 , 47( 1 ) :65 -81.
  • 4GESSNER A, OLBRICH C, SCHRODER W et al. The role of plasma proteins in brain targeling: Species dependent protein adsorption pallerns on brain-specific lipid drug conjugate ( LDC ) nanoparticles[J].Int J Pharm, 2001. 214( 1-2):87-91.
  • 5AMBRUOSI A.GELPERINA S.KHALANSKY A,et al.Influence of surfactants,polymer and doxorubicin loading on the antitumour effect of poly(butyl eyanoacrylate)nanoparticles in a rat glioma model[J].J Microencapsul, 23(5) :582 -592.
  • 6KREUTER J,KHARKEVICH DA.ALYAUTDIN RN,et al.Influence of the type of surfactant on the analgesic effects induced de dalargin after its delivery across the blood-brain barrier using surfactant-coaled nanoparticles[ J]. J Controlled Release, 1997, 49(1) :81 -87.
  • 7OLIVIER JC, FENART L, CHAUVET R, et al. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity[J]. Pharm Res, 1999, 16(12) :1836 - 1842.
  • 8FRIESE A, SEILLER E, QUACK G, et al. Increase of theduration of tile anticonvulsive activity of a novel nmda receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system [ J ]. Eur J Pharm Biopharm, 2000, 49 (2) :103 -109.
  • 9MICHAELIS K, HOFFMANN MM, DREIS S. et al. Covalent linkage of apolipoprolein E to albumin nanoparticles strongly enhances drug transport into the brain [J]. J Pharmacol Exp Ther 2006, 317(3) :1246-1253.
  • 10KIM HR, GIL S, ANDRIEUX K, et al. kow-density lipoprolein receptor-mediated endocytosis of pegylaled nanoparticles in rat brain endothelial cells [ J].Cell Mol Life Sci, 2007, 64 ( 3 ) : 356 - 364.

同被引文献26

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部